ImmuPharma Restarts Lupus Work; $76M Loan for Phase III
LONDON – Following an 18-month hiatus, ImmuPharma plc can now proceed with Phase III development of its lupus treatment, Lupuzor, after agreeing to a £50 million (US$75.7 million) loan to finance the trial.
Suite: 1100 | Atlanta, Georgia 30346, USA
Outside of the US
In the U.S. and Canada: +1-800-336-4474
Outside the U.S.: +44-203-684-1796
Hours: Monday - Friday, 8:00am - 6:00 pm EST
Sign up for Highlights FREE e-mail newsletter